Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II noninferiority study

Clinical Infectious Diseases

Volumn 60, Issue 2, 2015, Pages 254-262

  Ralph Corey, G ^a   Good, Samantha ^b   Jiang, Hai ^b   Moeck, Greg ^b   Wikler, Matthew ^b   Green, Sinikka ^c   Manos, Paul ^d   Keech, Richard ^b   Singh, Rajesh ^e   Heller, Barry ^b   Bubnova, Natalia ^b   O'Riordan, William ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Medicines Company ^*  (Russian Federation)

^c SHARP GROSSMONT HOSPITAL   (United States)

^d Paradise Valley Hospital   (United States)

^e GOVERNMENT MEDICAL COLLEGE   (India)

^f SHARP HEALTHCARE   (United States)

Author keywords

acute bacterial skin and skin structure infection (ABSSSI); lipoglycopeptide; methicillin resistant Staphylococcus aureus (MRSA); oritavancin; vancomycin

Indexed keywords

ORITAVANCIN; PLACEBO; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ABNORMAL LABORATORY RESULT; ABSCESS; ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ADULT; AGED; ARTICLE; BACTERIAL SKIN DISEASE; CELLULITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; INFECTION; INJECTION SITE EXTRAVASATION; INJECTION SITE PHLEBITIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; NAUSEA; OSTEOMYELITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN ABSCESS; TACHYCARDIA; TREATMENT OUTCOME; VOMITING; WOUND INFECTION; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; GRAM-POSITIVE BACTERIAL INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84924746136     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu778     Document Type: Article

References (34)

1. Corey GR, Stryjewski MW. New roles for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin Infect Dis 2011; 52(suppl 7):S469-76.
2. Elston DM. Optimal antibacterial treatment of uncomplicated skin and skin structure infections: applying a novel treatment algorithm. J Drugs Dermatol 2005; 4:S15-9.
3. Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococ-cus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA 2012; 308:50-9.
4. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis 2010; 51:895-903.
5. Lee BY, Singh A, David MZ, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect 2013; 19:528-36.
6. Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F; the REACH study group. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013; 19: E377-85.
7. Stevens DL, Bisno AL, Chambers HF, et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-406.
8. Liu C, Bayer A, Cosgrove SE, et al.; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
9. Teflaro prescribing information. Forest Laboratories, Inc. Available at: http://www.frx.com/pi/teflaro-pi.pdf. Accessed 15 October 2014.
10. Tygacil Prescribing Information. Pfizer, Inc. Available at: http://labeling. pfizer.com/showlabeling.aspx?id=491. Accessed 15 October 2014.
11. Vancomycin prescribing information. Pfizer Inc. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=661. Accessed 15 October 2014.
12. Vibativ prescribing information. Theravance Inc. Available at: http://www.vibativ.com/docs/VIBATIV-PI-Final.pdf. Accessed 15 October 2014.
13. Zyvox prescribing information. Pfizer Inc. Available at: http://labeling. pfizer.com/showlabeling.aspx?id=649. Accessed 15 October 2014.
14. Cubicin prescribing information. Cubist Pharmaceuticals, Inc. Available at: http://www.cubicin.com/pdf/PrescribingInformation.pdf. Accessed 15 October 2014.
15. Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007; 45:1705-11.
16. Centers for Disease Control and Prevention. Active Bacterial Core surveillance report, Emerging Infections Program Network, methicillin-re-sistant Staphylococcus aureus, 2011. Available at: http://www.cdc.gov/abcs/reports-findings/survreports/mrsa11.pdf. Accessed 15 October 2014.
17. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, 2012. Available at: http://ecdc.europa.eu/en/publica tions/Publications/antimicrobial-resistance-surveillance-europe-2011. pdf. Accessed 15 October 2014.
18. Ball AT, Xu Y, Sanchez RJ, Shelbaya A, Deminski MC, Nau DP. Non-adherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals. Clin Ther 2010; 32:2246-55.
19. Tice A. Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis 2012; 54:S239-43.
20. Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother 2009; 11: 4762-71.
21. Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 2012; 54(suppl 3):S203-13.
22. Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012; 54(suppl 3):S220-8.
23. McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009; 63: 1191-9.
24. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bac-teremia. Antimicrob Agents Chemother 2009; 53:4422-8.
25. Oritavancin prescribing information. The Medicines Company. Available at: http://www.themedicinescompany.com/app/webroot/img/orbactiv-prescribing-information.pdf. Accessed 15 October 2014.
26. Kumar A, Mann HJ, Keshtgarpour M, et al. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Int J Artif Organs 2011; 34:1067-74.
27. Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G. Pharma-codynamics of a simulated single 1, 200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamics model of methicillin-resistant Staphyloccocus aureus infection. Antimicrob Agents Chemo-ther 2013; 57:205-11.
28. Dunbar LM, Milata J, McClure T, Wasilewski MM; SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Anti-microb Agents Chemother 2011; 55:3476-84.
29. Corey GR, Kabler H, Mehra P, et al.; for the SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014; 370:2180-90.
30. Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment (draft guidance; 2010). Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185. pdf. Accessed 15 October 2014.
31. European Medicines Agency Committee for Medicinal Products for Human Use. Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CHMP/EWP/558/95 REV 2) to address indication-specific clinical data (draft), 2012. Available at: http://www.ema.europa.eu/docs/en-GB/docu ment-library/Scientific-guideline/2012/07/WC500129443.pdf. Accessed 15 October 2014.
32. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H; CAPB-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis 2012; 55:1114-21.
33. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. 2009. Available at: http://www.fda.gov/downloads/Drugs/../Guid ances/UCM174090.pdf. Accessed 15 October 2014.
34. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34:243-52.